Aptorum Group Ltd
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
APM | US
Overview
Corporate Details
- ISIN(s):
- KYG6096M1069
- LEI:
- Country:
- United States of America
- Address:
- 17 HANOVER SQUARE, LONDON
- Website:
- https://www.aptorumgroup.com/
- Sector:
- Manufacturing
Description
Aptorum Group Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to address unmet medical needs. The company's research and development pipeline targets a range of therapeutic areas, including orphan oncology, infectious diseases, and metabolic diseases. Key projects include SACT-1, a repurposed drug candidate for neuroblastoma, and ALS-4, an anti-virulence, non-bactericidal therapeutic for infections caused by Staphylococcus aureus. Additionally, the company is developing its RPIDD (Rapid Pathogen Identification and Detection Diagnostics) platform, a liquid biopsy-based technology for rapidly identifying and detecting pathogens.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Aptorum Group Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aptorum Group Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aptorum Group Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
